ArticleJournal of medicinal chemistry2010
Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs.
Article in Journal of medicinal chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- New small-molecule compound Hu-17 inhibits estrogen biosynthesis by aromatase in human ovarian granulosa cancer cells.Cancer medicine · 2020Article
- Predicted Biological Activity of Purchasable Chemical Space.Journal of chemical information and modeling · 2018Article
- A Simple Representation of Three-Dimensional Molecular Structure.Journal of medicinal chemistry · 2017Article
- Systems Pharmacology in Small Molecular Drug Discovery.International journal of molecular sciences · 2016Review
- Activity-Independent Discovery of Secondary Metabolites Using Chemical Elicitation and Cheminformatic Inference.ACS chemical biology · 2015Article
- Target prediction utilising negative bioactivity data covering large chemical space.Journal of cheminformatics · 2015Article
- Exploring the ligand-protein networks in traditional chinese medicine: current databases, methods and applications.Advances in experimental medicine and biology · 2015Article
- A combination of metabolic labeling and 2D-DIGE analysis in response to a farnesyltransferase inhibitor facilitates the discovery of new prenylated proteins.Molecular bioSystems · 2014Article
- Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).Biochemical pharmacology · 2013Article
- Exploring the ligand-protein networks in traditional chinese medicine: current databases, methods, and applications.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Small molecule inhibitors of Smoothened ciliary localization and ciliogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- An enzyme-coupled continuous fluorescence assay for farnesyl diphosphate synthases.Analytical biochemistry · 2012Article
- Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design.Chemical biology & drug design · 2011Article
- Target-specific support vector machine scoring in structure-based virtual screening: computational validation, in vitro testing in kinases, and effects on lung cancer cell proliferation.Journal of chemical information and modeling · 2011Article
- The chemical basis of pharmacology.Biochemistry · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The similarity ensemble approach (SEA) relates proteins based on the set-wise chemical similarity among their ligands. It can be used to rapidly search large compound databases and to build cross-target similarity maps. The emerging maps relate targets in ways that reveal relationships one might not recognize based on sequence or structural similarities alone. SEA has previously revealed cross talk between drugs acting primarily on G-protein coupled receptors (GPCRs). Here we used SEA to look for potential off-target inhibition of the enzyme protein farnesyltransferase (PFTase) by commercially available drugs. The inhibition of PFTase has profound consequences for oncogenesis, as well as a number of other diseases. In the present study, two commercial drugs, Loratadine and Miconazole, were identified as potential ligands for PFTase and subsequently confirmed as such experimentally. These results point toward the applicability of SEA for the prediction of not only GPCR-GPCR drug cross talk but also GPCR-enzyme and enzyme-enzyme drug cross talk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.